Clinical Trial Update: A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating high-dose post-transplant cyclophosphamide combined with bortezomib and abatacept to prevent graft-versus-host disease after…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Abatacept (abatacept)
• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: Northwell Health | Conditions: Graft Vs Host Disease | Phase 1, Phase 2 | Status: RECRUITING